OREXO AB SP/ADR - ORXOY STOCK NEWS

Sober Grid, a leading social media platform for addiction recovery, has partnered with Orexo to provide its users access to clinically validated digital therapeutics, vorvida® and deprexis®, starting August 2021. Vorvida® targets problematic alcohol use, while deprexis® addresses depression symptoms. These digital therapies utilize cognitive behavioral therapy and AI-driven personalization to enhance user experience. The collaboration aims to expand mental health accessibility, particularly for those hesitant to seek in-person treatment.

Orexo AB (OTCQX: ORXOY) has partnered with Sober Grid, enhancing access to its digital therapies vorvida® and deprexis® for over 300,000 users. The partnership aims to provide effective support for problematic alcohol use and depression. Available initially through Sober Grid's peer coaches in August 2021, the therapies will later be accessible to all users via the app, demonstrating Orexo's commitment to mental health support through innovative digital solutions.

Orexo AB (OTCQX: ORXOY) has enrolled the first participant in a pivotal study evaluating modia™, a digital therapeutic for opioid use disorder (OUD). This randomized study will assess modia™ combined with sublingual buprenorphine/naloxone for its effectiveness in reducing illicit opioid use, enrolling around 400 participants across the US. The opioid epidemic worsened during the COVID-19 pandemic, with over 67,500 fatalities linked to opioid overdoses. Orexo aims to address this gap in treatment options as part of their mission to improve substance use disorder responses.

Orexo AB announced the issuance of two new patents by the US Patent and Trademark Office for ZUBSOLV®, a sublingual tablet for opioid use disorder. These patents, expiring in September 2032, enhance Orexo's patent portfolio to nine patents listed in the Orange Book for ZUBSOLV®. CEO Nikolaj Sørensen emphasized the importance of these patents in maintaining the product's profitability and supporting long-term growth objectives.

Orexo reported Q1 2021 net revenues of SEK 132.3 million, down 24% compared to the same period in 2020. Net earnings were SEK -31.5 million and EBITDA was SEK -23.9 million. The US Pharma segment generated SEK 126.8 million in revenues. Cash flow from operations decreased to SEK -47.8 million, with a cash balance of SEK 725.5 million. Orexo secured new patents for OX124 and ZUBSOLV®. A partnership with Magellan Rx was established to test modia™.

Orexo AB (OTCQX: ORXOY) announced a collaboration with ApexB.io and Magellan Rx Management to research its digital therapeutic modia™, aimed at treating opioid use disorder (OUD). The partnership seeks to gather real-world evidence supporting the digital treatment's accessibility. This initiative aligns with CDC calls to combat rising overdose deaths, which surged by 21% to over 83,000 in the U.S. in the past year. Orexo is also advancing other digital therapeutics, deprexis® and vorvida®, in response to growing mental health challenges.

Orexo announces the early redemption of its SEK 500 million senior unsecured callable floating rate bonds originally due in 2021. The bonds will be redeemed in full on March 3, 2021, at a price of 101.50% of the nominal amount plus accrued interest. The record date for this redemption is set for February 24, 2021. To facilitate this process without default, Orexo has received a temporary waiver from the bond agent. Following the redemption, the bonds will be delisted from Nasdaq Stockholm.

Orexo AB has successfully issued senior unsecured callable floating rate bonds worth SEK 500 million, oversubscribed under a SEK 1,000 million framework, maturing in February 2025. These bonds carry a floating interest rate of 3-month Stibor + 375bps per annum and received strong interest from institutional investors. The funds will facilitate the repurchase of existing bonds totaling SEK 77.4 million and early redemption of SEK 148.5 million. This signals investor confidence in Orexo's growth strategy in developing its pipeline and digital therapeutics.

On February 1, 2021, Orexo AB announced its plans to issue senior unsecured callable floating rate bonds worth up to SEK 500 million under a total framework of SEK 1,000 million with a four-year tenor. The proceeds will be used to repay existing bonds and support general corporate purposes. Existing bondholders may subscribe to the new bonds or opt for a premium repurchase of their current holdings. The company aims to enhance its financial flexibility for future investments.